当前位置： SCI文献检索 > CLINICAL THERAPEUTICS期刊下所有文献 > Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

Abstract：

BACKGROUND:Panitumumab, formerly known as ABX-EGF, was the first recombinant human immunoglobulin G2 monoclonal antibody approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. OBJECTIVE:The purpose of this review was to evaluate the pharmacokinetic and pharmacodynamic properties, clinical efficacy, and safety profile of panitumumab in the treatment of metastatic colorectal cancer. METHODS:Computerized searches of MEDLINE and International Pharmaceutical Abstracts from 1985 to August 15, 2007, were performed with the search terms panitumumab, ABX-EGF, EGFr, and colorectal cancer. All available clinical trials and ongoing trials were included in this review. Relevant abstracts presented at the annual meetings of the American Society of Clinical Oncology, American Association for Cancer Research, and Gastrointestinal Cancer Symposium (1999-2007) also were reviewed and included. RESULTS:Preclinical and clinical studies have established a role for panitumumab in mCRC refractory to multiple chemotherapeutic regimens. In a Phase III trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with refractory mCRC, panitumumab was found to have efficacy in time-related end points, such as progression-free survival. In the panitumumab group, a significant (46%) reduction in tumor progression rate was reported compared with BSC (hazard ratio, 0.54; 95% CI, 0.44-0.66; P < 0.001). At the present time, the use of panitumumab as first-line treatment for mCRC with standard chemotherapy and bevacizumab is not indicated due to increased toxicity with no advantage in efficacy. The efficacy of panitumumab is being evaluated in other solid tumors, such as lung, breast, ovarian, bladder, and head and neck cancers. CONCLUSION:Panitumumab appears to have relatively acceptable tolerability and is now available as an additional option for patients with mCRC refractory to multiple chemotherapeutic regimens.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Wu M,Rivkin A,Pham T

doi

10.1016/j.clinthera.2008.01.014

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

14-30

issue

1

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(08)00062-3

journal_volume

30

pub_type

杂志文章,评审

相关文献

CLINICAL THERAPEUTICS文献大全
  • COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.

    abstract：:Against the backdrop of the COVID pandemic, the scientific and medical communities are working with all deliberate speed with state-of-the-art technologies to develop diagnostic and therapeutic products that can identify, treat, and prevent infection with SARS-CoV-2. These activities may only be legally conducted with...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2020.06.014

    authors： Beninger P

    更新日期：2020-08-01 00:00:00

  • The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.

    abstract：BACKGROUND:In vitro studies have demonstrated that ticagrelor, an oral antiplatelet agent, is a substrate, activator, and inhibitor of cytochrome P450 (CYP) 3A. Thus, potential CYP3A-mediated drug-drug interactions may occur. OBJECTIVES:The goal of this article was to report study results on the effect of ticagrelor o...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2013.06.003

    authors： Teng R,Butler K

    更新日期：2013-07-01 00:00:00

  • Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.

    abstract：PURPOSE:Samidorphan (3-carboxamido-4-hydroxy naltrexone) is a novel opioid receptor antagonist that is currently in clinical development. The oral dose pharmacokinetics, safety, and tolerability of samidorphan were evaluated in 2 double-blind, placebo-controlled, randomized studies in healthy adults. METHODS:The first...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2014.10.001

    authors： Turncliff R,DiPetrillo L,Silverman B,Ehrich E

    更新日期：2015-02-01 00:00:00

  • Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.

    abstract：BACKGROUND:New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment in progression-free survival (PFS) ranging from 2 to 6 months. Compared with best supportive care, everolimus demonstrated an additional PFS of 3 months in patients with mRCC whose disease had progressed on sunitinib and...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2013.10.004

    authors： Mihajlović J,Pechlivanoglou P,Sabo A,Tomić Z,Postma MJ

    更新日期：2013-12-01 00:00:00

  • Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.

    abstract：PURPOSE:Although the efficacy of canagliflozin has been well established in clinical trials, research regarding its use and impact on outcomes in clinical practice has been limited by the availability of data on observations up to and beyond 6 months after the initial use of canagliflozin. The purpose of this study was...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2016.07.009

    authors： Bailey RA,Schwab P,Xu Y,Pasquale M,Renda A

    更新日期：2016-09-01 00:00:00

  • Postpartum endometritis: efficacy and tolerability of two antibiotic regimens.

    abstract：:A prospective, multicenter, open-label randomized trial was conducted to compare the efficacy and tolerability of imipenem-cilastatin (I-C) monotherapy with clindamycin+aminoglycoside (C+A) combination therapy. Forty-nine patients were able to be evaluated for clinical efficacy in the treatment of postpartum endometri...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Gonik B

    更新日期：1992-01-01 00:00:00

  • Women and the Experience of Pain and Opioid Use Disorder: A Literature-based Commentary.

    abstract：:It is generally understood that pain experience and opioid abuse have relied on male-dominated models. However, sex and gender play a role in both pain experience and opioid use disorder. Using the previously validated Texas Tech University Health Sciences Center Sex and Gender Specific Health PubMed Advanced Search T...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.12.016

    authors： Koons AL,Rayl Greenberg M,Cannon RD,Beauchamp GA

    更新日期：2018-02-01 00:00:00

  • Granisetron versus granisetron/dexamethasone combination for the treatment of nausea, retching, and vomiting after major gynecologic surgery: a randomized, double-blind study.

    abstract：BACKGROUND:Granisetron, a selective 5-hydroxytryptamine3 antagonist, is effective for the treatment of patients with postoperative nausea and vomiting. Dexamethasone decreases chemotherapy-induced emesis when added to an antiemetic regimen. OBJECTIVE:This study compared the efficacy of granisetron alone with granisetr...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验,收录出版

    doi：10.1016/s0149-2918(03)80092-9

    authors： Fujii Y,Tanaka H

    更新日期：2003-02-01 00:00:00

  • Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

    abstract：:This multicenter, randomized, double-blind study compared the efficacy and tolerability of ondansetron 8 mg twice daily for 3 days with placebo in preventing nausea and vomiting in 81 patients receiving cyclophosphamide-doxorubicin-based chemotherapy. The first dose of study drug was administered 30 minutes before the...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1016/0149-2918(95)80087-5

    authors： DiBenedetto J Jr,Cubeddu LX,Ryan T,Kish JA,Sciortino D,Beall C,Eisenberg PD,Henderson C,Griffin D,Wentz A

    更新日期：1995-11-01 00:00:00

  • Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.

    abstract：PURPOSE:The goal of this study was to assess the long-term safety and efficacy of mepolizumab in patients with the most severe eosinophilic asthma. METHODS:This multicenter, open-label, long-term, Phase IIIb study (COSMEX [COSMOS Extension]; 201312/NCT02135692) enrolled patients from the 52-week, open-label extension ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clinthera.2019.07.007

    authors： Khurana S,Brusselle GG,Bel EH,FitzGerald JM,Masoli M,Korn S,Kato M,Albers FC,Bradford ES,Gilson MJ,Price RG,Humbert M

    更新日期：2019-10-01 00:00:00

  • Optimizing oral medications for children.

    abstract：BACKGROUND:Active pharmaceutical ingredients that taste bitter and/or irritate the mouth and throat are aversive to children as well as many adults. Effective methods of avoiding unpleasant tastes for adults (eg, encapsulating the medicine in pill, capsule, or tablet form) are problematic because many children cannot o...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2008.11.018

    authors： Mennella JA,Beauchamp GK

    更新日期：2008-11-01 00:00:00

  • Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

    abstract：PURPOSE:This study examined the utility of therapeutic drug monitoring (TDM) of imatinib, nilotinib, and dasatinib in adult patients with chronic-phase chronic myeloid leukemia (CML). TDM in CML entails the measurement of plasma tyrosine kinase inhibitor (TKI) concentration to predict efficacy and tolerability outcomes...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clinthera.2019.10.009

    authors： García-Ferrer M,Wojnicz A,Mejía G,Koller D,Zubiaur P,Abad-Santos F

    更新日期：2019-12-01 00:00:00

  • Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    abstract：OBJECTIVE:This study evaluated the efficacy and tolerability of glimepiride in patients with type 2 diabetes mellitus that was inadequately controlled with a combination of immediate- or extended-release metformin and a thiazolidinedione. METHODS:This was a multicenter, randomized, double-blind, placebo-controlled, pa...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clinthera.2005.10.017

    authors： Roberts VL,Stewart J,Issa M,Lake B,Melis R

    更新日期：2005-10-01 00:00:00

  • Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.

    abstract：BACKGROUND:Respiratory syncytial virus (RSV) lower respiratory tract infection (LRI) in early life has been associated with sustained airway hyperreactivity during childhood; however, corresponding data in premature infants are sparse. OBJECTIVE:The objective of this study was to determine whether RSV-LRI during early...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2011.01.007

    authors： Romero JR,Stewart DL,Buysman EK,Fernandes AW,Jafri HS,Mahadevia PJ

    更新日期：2010-12-01 00:00:00

  • Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.

    abstract：BACKGROUND:Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by mutations in the survival motor neuron gene (SMN1) and the leading genetic cause of infant mortality. Currently, there is no effective treatment other than supportive care. OBJECTIVE:This article provides a general overvi...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2013.11.006

    authors： Zanetta C,Nizzardo M,Simone C,Monguzzi E,Bresolin N,Comi GP,Corti S

    更新日期：2014-01-01 00:00:00

  • Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial.

    abstract：:A national multicentre trial was organized in order to compare the efficacy and safety of leuprorelin acetate depot and danazol in the treatment of endometriosis. Sixty-seven patients with pelvic endometriosis of different severity at laparoscopy were included in the study and followed during the 24 weeks of treatment...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Crosignani PG,Gastaldi A,Lombardi PL,Montemagno U,Vignali M,Serra GB,Stella C

    更新日期：1992-01-01 00:00:00

  • The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan.

    abstract：:The objective of this 12-week, double-masked, randomized, multicenter study was to compare the elastoviscous properties of a high-molecular-weight viscosupplement, hylan G-F 20 (polymer concentration, 0.8%), with those of a lower-molecular-weight hyaluronan (LMW HA) product (polymer concentration, 1%) and to determine...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1016/s0149-2918(00)80010-7

    authors： Wobig M,Bach G,Beks P,Dickhut A,Runzheimer J,Schwieger G,Vetter G,Balazs E

    更新日期：1999-09-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

    abstract：:The pharmacodynamic parameter that appears to correlate best with a successful therapeutic outcome with beta-lactam antibiotics is the length of time the serum antibiotic concentration remains above the minimum inhibitory concentration (MIC) for the infecting pathogen. By maximizing this parameter, continuous administ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/S0149-2918(00)86736-3

    authors： Burgess DS,Summers KK,Hardin TC

    更新日期：1999-11-01 00:00:00

  • Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature.

    abstract：INTRODUCTION:Acute generalized exanthematous pustulosis (AGEP) is a clinical reaction pattern that is principally drug induced and is characterized by acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous substrate. Hydroxychloroquine (HHCQ), an antimalarial drug widely used to t...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2008.05.014

    authors： Paradisi A,Bugatti L,Sisto T,Filosa G,Amerio PL,Capizzi R

    更新日期：2008-05-01 00:00:00

  • A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.

    abstract：BACKGROUND:Oxymorphone extended release (ER) is a tablet formulation of the mu-opioid agonist oxymorphone designed to achieve a low peak-to-trough fluctuation in plasma concentrations over a 12-hour dosing period. OBJECTIVE:This study compared the analgesic efficacy, dose response, and tolerability of 3 doses of oxymo...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clinthera.2006.03.008

    authors： Kivitz A,Ma C,Ahdieh H,Galer BS

    更新日期：2006-03-01 00:00:00

  • Long-term Clinical and Cost Outcomes of a Pharmacist-managed Risk Factor Management Clinic in Singapore: An Observational Study.

    abstract：PURPOSE:Few studies have determined the benefits of pharmacist-run clinics within a tertiary institution, and specifically on their capability to improve clinical outcomes as well as reduce the cost of illness. This study was designed to investigate the effectiveness of a pharmacist-managed risk factor management clini...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.10.009

    authors： Tan SH,Kng KK,Lim SM,Chan A,Loh JKK,Lee JY

    更新日期：2017-12-01 00:00:00

  • Update on disease-modifying treatments for multiple sclerosis.

    abstract：PURPOSE:The purpose of this review is to discuss the selection and use of disease- modifying treatments for patients with relapsing forms of multiple sclerosis (MS). METHODS:PubMed was searched (1966-2014) using the terms multiple sclerosis, treatment, interferon, glatiramer acetate, dimethyl fumarate, fingolimod, ter...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2014.08.006

    authors： Carrithers MD

    更新日期：2014-12-01 00:00:00

  • Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.

    abstract：BACKGROUND:In patients with type 2 diabetes, published data suggest that glycemic control can be achieved as effectively with an inhaled insulin regimen (preprandial inhaled intrapulmonary insulin plus a single bedtime Ultralente injection) as with a conventional subcutaneous insulin regimen involving 2 to 3 injections...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0149-2918(02)85131-1

    authors： Cappelleri JC,Cefalu WT,Rosenstock J,Kourides IA,Gerber RA

    更新日期：2002-04-01 00:00:00

  • The origin of bacteria isolated from patients after transurethral prostatectomy.

    abstract：:Of 250 patients undergoing transurethral prostatectomy, 34 had significant bacteriuria after surgery. In 20 patients, including some without significant colonies of bacteria, the same organisms were found before surgery. Closed surgical systems and aseptic techniques can prevent infection from outside the patient, but...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Fujita K

    更新日期：1988-01-01 00:00:00

  • Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis.

    abstract：BACKGROUND:Rates of patient adherence (compliance) to pharmacotherapy range from <5% to >90%. Negative determinants include multiple daily dosing (MDD), chronic duration, and asymptomatic disease. Reports suggest that once-daily (QD) dosing may improve adherence, but their findings are inconclusive. OBJECTIVE:The purp...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1016/s0149-2918(02)85026-3

    authors： Iskedjian M,Einarson TR,MacKeigan LD,Shear N,Addis A,Mittmann N,Ilersich AL

    更新日期：2002-02-01 00:00:00

  • Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

    abstract：OBJECTIVES:This study was conducted to estimate the prevalence of antipsychotic polypharmacy among fee-for service state Medicaid beneficiaries initiating antipsychotic drug therapy and to investigate psychiatric and demographic predictors of such polypharmacy. METHODS:This was a retrospective cohort study employing M...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2007.01.002

    authors： Morrato EH,Dodd S,Oderda G,Haxby DG,Allen R,Valuck RJ

    更新日期：2007-01-01 00:00:00

  • Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.

    abstract：BACKGROUND:Desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI), was approved by the US Food and Drug Administration (FDA) in February 2008 for the treatment of adult patients with major depressive disorder (MDD). Desvenlafaxine is the third SNRI approved by the FDA for this indication. OBJEC...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2009.07.012

    authors： Perry R,Cassagnol M

    更新日期：2009-06-01 00:00:00

  • Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.

    abstract：BACKGROUND:Hereditary angioedema (HAE) is a rare, potentially life-threatening autosomal dominant disease characterized by recurrent angioedema attacks that affect the skin, gastrointestinal tract, and airway, including the larynx. Pharmacologic developments in HAE treatment have culminated in the recent introduction o...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2012.02.003

    authors： Riedl M

    更新日期：2012-03-01 00:00:00

  • Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

    abstract：BACKGROUND:The emergence of multidrug-resistant nosocomial pathogens, such as Pseudomonas aeruginosa and Acinetobacter baumannii, has led to the revival of the systemic use of antimicrobial agent colistin in critically ill patients, but only limited data are available to define its pharmacokinetic profile in these pati...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.clinthera.2008.01.015

    authors： Markou N,Markantonis SL,Dimitrakis E,Panidis D,Boutzouka E,Karatzas S,Rafailidis P,Apostolakos H,Baltopoulos G

    更新日期：2008-01-01 00:00:00

  • Twenty-eight-day oral contraceptives: physician and user attitudes.

    abstract：:A 28-day regimen of oral contraceptives that uses seven iron tablets (each containing 75 mg of ferrous fumarate) instead of seven sugar placebos was designed to encourage user compliance. To determine professional and user attitudes toward the 28-day regimen, 192 obstetrician-gynecologists and 469 women who used oral ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Richards-Brandt M

    更新日期：1988-01-01 00:00:00